Prenetics Global Stock Plunges 8% as Q1 Loss Widens Beyond Analyst Estimates
Summary
Prenetics Global's stock plunged 8.2% after the company reported a first-quarter loss from continuing operations of $1.61 per share, significantly wider than the $1.02 per share analysts had expected. This finalized Q1 result, which follows the 6-K filed earlier today, highlights a deeper-than-anticipated loss despite revenue meeting projections and Q2 guidance exceeding expectations. The market is reacting negatively to the earnings miss on the bottom line, contrasting with the company's recent positive announcements regarding IM8 brand growth and strategic partnerships.
At the time of this announcement, PRE was trading at $19.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $320.1M. The 52-week trading range was $6.88 to $23.63. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.